Efficacy and Safety of Trametinib in <scp>Non-V600 <i>BRAF</i> </scp> Mutant Melanoma: A Phase II Study

Abstract

In contrast to recently described tumor-agnostic studies in a genetically similar population, trametinib had considerable activity in a small population of patients with melanoma harboring BRAF non-V600 mutations and fusions, providing rationale for sequencing in search of these genomic alterations.